NCT02787551: A reported trial by Sanofi
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02787551 |
|---|---|
| Title | A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 6, 2016 |
| Completion date | May 25, 2018 |
| Required reporting date | May 25, 2019, midnight |
| Actual reporting date | May 23, 2019 |
| Date last checked at ClinicalTrials.gov | Nov. 17, 2025 |
| Days late | None |